Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2010-09-28 Capital/Financing Update
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
Solid Uptake in Rights Issue 1 page ?Kb
Capital/Financing Update Classification · 95% confidence The document is a short announcement dated 29 September 2010 from Phylogica Ltd regarding the closing and results of a renounceable rights issue. It details the number of shares subscribed, the shortfall taken up by the underwriter, the amount raised, and the intended use of proceeds. There are no financial statements or detailed financial analysis included, and the document is only 1416 characters long, indicating it is a brief update rather than a full report. This fits the definition of a Capital/Financing Update (CAP), which covers company fundraising and capital structure changes.
2010-09-28 English
Full Year Statutory Accounts 51 pages ?Kb
Annual Report Classification · 100% confidence The document is titled 'Financial Report 30 June 2010' and contains detailed sections typical of an annual financial report, including Directors' Report, Auditor's Independence Declaration, comprehensive financial statements (Statement of Comprehensive Income, Statement of Financial Position, Statement of Cash Flows, Statement of Changes in Equity), Notes to the Financial Statements, Directors' Declaration, Independent Auditor's Report, Corporate Governance Statement, and ASX additional information. The presence of these detailed financial statements and audit reports for the full fiscal year ending 30 June 2010 indicates this is a full Annual Report. The document length (15,000 characters) and content confirm it is the report itself, not just an announcement or summary. Therefore, the appropriate classification is Annual Report (10-K). FY 2010
2010-09-27 English
Change of Director`s Interest Notice 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a director's acquisition of shares, including the number of securities held before and after the change, the date of change, and the nature of the transaction (on-market purchase). This is a clear report of a personal share transaction by a company director. The document length is 2630 characters, which is consistent with a detailed notice of director dealings rather than a full financial report or announcement. Therefore, the document fits the definition of 'Director's Dealing' (DIRS).
2010-09-22 English
Interview with Mr Nick Woolf Non Executive Director 1
Capital/Financing Update Classification · 95% confidence The document is an announcement of an audio broadcast interview with a Non-Executive Director of Phylogica Limited discussing a company update and a recently announced rights issue. The document is short (1057 characters) and does not contain any financial statements or detailed financial data. It primarily serves as a notification about the rights issue and provides a link to the company's media center for further information. Therefore, it is an update related to company fundraising activities, specifically a rights issue, which falls under Capital/Financing Update (CAP).
2010-09-21 English
Despatch of Right Issue Documents 1 page ?Kb
Capital/Financing Update Classification · 95% confidence The document is a short announcement dated 10 September 2010 from Phylogica Limited regarding the completion of dispatch to shareholders of the Renounceable Rights Issue Prospectus and Entitlement Form. It is an update about a financing activity (rights issue) and does not contain financial statements or detailed financial data. The document length is only 754 characters, indicating it is a brief announcement rather than a full report. Therefore, it fits the category of Capital/Financing Update (CAP).
2010-09-09 English
Further Statement Licensing Agreement 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a company announcement clarifying previous statements about a licensing agreement with MedImmune. It discusses payment terms, milestone payments, and corrects earlier statements to avoid misleading investors. There is no financial report, earnings data, or detailed financial statements. The document is a regulatory announcement clarifying prior disclosures and providing updated information to shareholders and the market. It does not fit into categories like Annual Report, Earnings Release, or Capital Update. It is a regulatory filing clarifying prior announcements and correcting information, which fits best under Regulatory Filings (RNS). The document length is under 5,000 characters and is a standalone announcement, not a report publication announcement or a full report.
2010-09-07 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.